201 related articles for article (PubMed ID: 23799412)
1. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma.
Robertson MJ; Kline J; Struemper H; Koch KM; Bauman JW; Gardner OS; Murray SC; Germaschewski F; Weisenbach J; Jonak Z; Toso JF
J Immunother; 2013; 36(6):331-41. PubMed ID: 23799412
[TBL] [Abstract][Full Text] [Related]
2. A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.
Robertson MJ; Stamatkin CW; Pelloso D; Weisenbach J; Prasad NK; Safa AR
J Immunother; 2018 Apr; 41(3):151-157. PubMed ID: 29517616
[TBL] [Abstract][Full Text] [Related]
3. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM
Clin Cancer Res; 2008 Jun; 14(11):3462-9. PubMed ID: 18519778
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
5. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
6. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma.
Zhao W; Gao Y; Bai B; Cai QC; Wang XX; Cai QQ; Huang HQ
Expert Opin Drug Saf; 2015 Jan; 14(1):21-9. PubMed ID: 25412839
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
Ansell SM; Witzig TE; Kurtin PJ; Sloan JA; Jelinek DF; Howell KG; Markovic SN; Habermann TM; Klee GG; Atherton PJ; Erlichman C
Blood; 2002 Jan; 99(1):67-74. PubMed ID: 11756154
[TBL] [Abstract][Full Text] [Related]
10. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20
Gopal AK; Levy R; Houot R; Patel SP; Popplewell L; Jacobson C; Mu XJ; Deng S; Ching KA; Chen Y; Davis CB; Huang B; Fly KD; Thall A; Woolfson A; Bartlett NL
Clin Cancer Res; 2020 Jun; 26(11):2524-2534. PubMed ID: 32144134
[TBL] [Abstract][Full Text] [Related]
11. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.
Timmerman JM; Byrd JC; Andorsky DJ; Yamada RE; Kramer J; Muthusamy N; Hunder N; Pagel JM
Clin Cancer Res; 2012 Oct; 18(20):5752-60. PubMed ID: 22893631
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Gerecitano J; Portlock C; Hamlin P; Moskowitz CH; Noy A; Straus D; Schulman P; Dumitrescu O; Sarasohn D; Pappanicholaou J; Iasonos A; Zhang Z; Mo Q; Horanlli E; Rojas CN; Zelenetz AD; O'Connor OA
Clin Cancer Res; 2011 Apr; 17(8):2493-501. PubMed ID: 21346146
[TBL] [Abstract][Full Text] [Related]
16. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma.
Martinelli G; Laszlo D; Bertolini F; Pastano R; Mancuso P; Calleri A; Vanazzi A; Santoro P; Cavalli F; Zucca E
Br J Haematol; 2003 Oct; 123(2):271-7. PubMed ID: 14531908
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
19. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Tran L; Baars JW; Aarden L; Beijnen JH; Huitema AD
Hum Antibodies; 2010; 19(1):7-13. PubMed ID: 20555126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]